PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le lundi 03.02.2020 à 10:00 AM CET
Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO2015173258) SOLUTION PHARMACEUTIQUE COMPRENANT DE LA DOPAMINE, DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DE LA MALADIE DE PARKINSON
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

CLAIMS

1. A pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its administration.

2. The pharmaceutical solution for use according to claim 1, wherein dopamine is dopamine hydrochloride.

3. The pharmaceutical solution for use according to any of claim 1 or 2, wherein the pharmaceutical solution is free of preservative agent.

4. The pharmaceutical composition for use according to any of claims 1 to 3, wherein said solution is adapted to be administered into brain ventricle, preferably into right lateral ventricle, preferably close to the interventricular foramen.

5. The pharmaceutical solution for use according to any of claims 1 to 4, wherein said solution is adapted to be administered with an anaerobical pump.

6. The pharmaceutical solution for use according to any of claims 1 to 5, wherein said solution is continuously administered with doses' variations.

7. The pharmaceutical solution for use according to any of claims 1 to 6, wherein said solution is administered with a predominant diurnal dose or with an exclusive diurnal dose.

8. The pharmaceutical solution for use according to any of claims 1 to 7, wherein said solution is administered with the following dosage regimen:

a continuous and stable diurnal dose,

a bolus administered on morning, and

optionally, at least a bolus when required, and/or

optionally, a continuous and stable nocturnal dose lower than the diurnal dose, preferably at least 25% lower than the diurnal dose, more preferably at least 50%

lower than the diurnal dose, more preferably at least 70% lower than the diurnal dose, more preferably at least 80% lower than the diurnal dose, more preferably at least 90% lower than the diurnal dose.